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Abstract
Background: Inflammation occurs as an immediate protective response of the immune system to a harmful stimulus,
whether locally confined or systemic. In contrast, a persisting, i.e., chronic, inflammatory state, even at a low-grade, is a
well-known risk factor in the development of common diseases like diabetes or atherosclerosis. In clinical practice,
laboratory markers like high-sensitivity C-reactive protein (hsCRP), white blood cell count (WBC), and fibrinogen, are
used to reveal inflammatory processes. In order to gain a deeper insight regarding inflammation-related changes in
metabolism, the present study assessed the metabolic patterns associated with alterations in inflammatory markers.
Methods: Based on mass spectrometry and nuclear magnetic resonance spectroscopy we determined a comprehensive
panel of 613 plasma and 587 urine metabolites among 925 apparently healthy individuals. Associations between inflammatory
markers, namely hsCRP, WBC, and fibrinogen, and metabolite levels were tested by linear regression analyses controlling for
common confounders. Additionally, we tested for a discriminative signature of an advanced inflammatory state using random
forest analysis.
Results: HsCRP, WBC, and fibrinogen were significantly associated with 71, 20, and 19 plasma and 22, 3, and 16 urine
metabolites, respectively. Identified metabolites were related to the bradykinin system, involved in oxidative stress (e.g.,
glutamine or pipecolate) or linked to the urea cycle (e.g., ornithine or citrulline). In particular, urine 3’-sialyllactose was
found as a novel metabolite related to inflammation. Prediction of an advanced inflammatory state based solely on 10
metabolites was well feasible (median AUC: 0.83).
Conclusions: Comprehensive metabolic profiling confirmed the far-reaching impact of inflammatory processes on
human metabolism. The identified metabolites included not only those already described as immune-modulatory but
also completely novel patterns. Moreover, the observed alterations provide molecular links to inflammation-associated
diseases like diabetes or cardiovascular disorders.
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Background
Inflammation is a corporeal response to damaging stim-
uli associated with the activation of various molecular
mechanisms. In addition to localized inflammatory reac-
tions at the site of injury (redness, swelling, overheating,
pain and disturbed function of the affected tissue or
organ), reactions of the entire organism can be affected,
depending on the severity of inflammation [1]. Both the
local and systemic responses initiated by an inflamma-
tory process indicate an imbalance in metabolism in the
tissues affected. The metabolic disequilibrium at the site
of injury is caused by the increased immune cell number
(cells of the immune system flow through the increased
blood flow to the injury site) and the diverse metabolic
requirements of immune cells, which differ from those
of local cells [2]. In addition to a general feeling of
illness, there are a number of different inflammatory pa-
rameters that are of clinical importance, including high-
sensitivity C-reactive protein (hsCRP), white blood cell
count (WBC), and fibrinogen. Localized and systemic in-
flammatory reactions with changes in the classical in-
flammatory parameters are indications of the altered
metabolism in the affected tissue [2]. After remission of
the inflammatory response, tissue metabolism normal-
izes. If the remission process is interrupted, for example,
due to persistence of pathogens, toxins, or other stimuli,
damage of healthy tissue could occur. With respect to
metabolic disease (e.g., diabetes), damage might be in-
duced due to the adverse effect of over nutrition as the
derived lipid species are able to induce the inflammatory
response, i.e., induction of cytokine release, in resistant
macrophages located in adipose tissue [3]. In general,
chronic inflammation is considered integral to the devel-
opment of serious systemic diseases such as type 2
diabetes mellitus (T2DM), cardiovascular diseases,
gastrointestinal disorders, and rheumatoid arthritis.
CRP and fibrinogen are acute phase proteins [4] that
are secreted from the liver upon interleukin 6 (IL-6)
stimulation; IL-6 is released by activated macrophages
and T cells. The primary role of CRP is binding to
phospholipid species of damaged cells or pathogens to
initiate the complement system. As the cause of tissue
damage could be from various sources, elevations in
hsCRP reflect a general inflammatory response rather
than being attributed to a specific cause [5]. Another
routinely measured indicator of systemic inflammation
in particular is WBC [6]. Studies have shown elevated
WBC levels not only during infection [7], but also in
relation to cardiovascular diseases [8], T2DM [9], or
metabolic syndrome [10]. Thus, all three inflammatory
markers – hsCRP, fibrinogen, and WBC – are clinically
useful in the diagnosis and follow-up of diseases.
Considering the close link of (chronic) inflammation
with common diseases and its burden on the patient and
the health system, improving the understanding about
the metabolic implications of low-grade chronic inflam-
matory processes is an urgent need. A suitable tool for
this purpose is metabolic profiling, as it allows the investi-
gation of a broad range of small molecules (metabolites)
in various body fluids. Consequently, the analysis of these
metabolites in relation to inflammatory markers such as
hsCRP, WBC, or fibrinogen enables the identification of
alterations at the molecular level and thereby characterizes
the (subclinical) inflammatory state. Previous studies have
identified metabolites such as fatty acids, like arachidonic
acid or palmitate, various lysophosphatidylcholines
(lysoPC) (18:1 and 18:2), metabolites of purine metabol-
ism, and amino acids associated with inflammatory
processes in patients suffering from obesity [11], T2DM
[12, 13], and their complications [14, 15].
To gain a deeper insight into inflammation-related
metabolism, the present study combined non-targeted,
i.e., based on liquid-chromatography coupled with tan-
dem mass spectrometry (LC-MS/MS), and targeted, i.e.,
based on high-performance LC-MS/MS and 1H-NMR
spectroscopy, metabolomics approaches. Through an in-
vestigation of metabolic patterns associated with alter-
ations in hsCRP, WBC, and fibrinogen levels in humans in
both plasma and urine, we are the first to generate a com-
pilation of metabolites spanning multiple pathways, thus
providing a link between metabolism and inflammation in
a large non-diabetic sample of the general population.
Methods
Study population
The Study of Health in Pomerania (SHIP-TREND) is a
population-based study located in West Pomerania, a
rural region in north-east Germany [16]. A stratified
(age, sex, and city/country of residence), random sample
of 8826 adults aged 20–79 years was drawn from popu-
lation registries. Sample selection was facilitated by
centralization of local population registries in the
Federal State of Mecklenburg, West Pomerania. Baseline
examinations were conducted between 2008 and 2012.
In total, 4420 subjects chose to participate (50.1%
response). All participants gave written informed
consent before taking part in the study. The study was
approved by the ethics committee of the University of
Greifswald and conformed to the principles of the
Declaration of Helsinki. SHIP data are publicly available
for scientific and quality control purposes. Data usage
can be applied for via www.community-medicine.de.
Plasma and urine metabolomics data based on MS and
NMR were available for a subsample of up to 1000 sub-
jects without diabetes (self-reported). To address the aims
of the present study we had to exclude subjects with miss-
ing values in inflammatory markers or confounding factors
(n = 47), as well as those with acute inflammation defined
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as hsCRP > 10 mg/L (n = 28). In total, the present study
comprised 925 subjects (Additional file 1: Figure S1).
Laboratory measurements and phenotypic
characterization
Smoking status (current, former or never smokers), daily
alcohol consumption, and physical activity (≥1 h training a
week) were assessed using computer-aided personal inter-
views. Waist circumference was measured to the nearest
0.1 cm using an inelastic tape midway between the lower
rib margin and the iliac crest in the horizontal plane.
Fasting blood samples were taken from the cubital
vein of participants in the supine position between
7.00 a.m. and 12.00 p.m. Over the same time span, spot
urine samples were taken. Except for hsCRP and cystatin
C, all clinical assays were performed using fresh plasma/
serum samples. To this end, blood samples were imme-
diately placed on ice. On average, 50 minutes elapsed
between blood collection and measurement. Further,
serum, EDTA-plasma, and urine samples were immedi-
ately partitioned into multiple aliquots and stored in a
centralized biobank at –80 °C. Out of the frozen
samples, metabolomics and hsCRP measurements were
performed after completion of the study with an average
storage time of 4.25 years. Fibrinogen concentrations
were determined in citrate plasma samples according to
Clauss, using a BCS-XP system (Siemens Healthcare
Diagnostics, Eschborn, Germany). WBC concentration
was determined in EDTA whole blood samples using the
Sysmex XT 2000, XE 5000, or SE9000 analyzers
(Sysmex, Kobe, Japan) or the Advia 2120i (Siemens
Healthcare Diagnostics). Three levels of control material
were measured by skilled technical personnel. Glucose,
triglyceride, alanine aminotransferase, and hsCRP con-
centrations were measured using the Dimension Vista
500 analytical system (Dimension VISTA, Siemens
Healthcare Diagnostics). Serum cystatin C concentra-
tions were measured using a nephelometric assay (Di-
mension VISTA, Siemens Healthcare Diagnostics) with a
functional sensitivity of 0.05 mg/L. Cystatin C-based es-
timated glomerular filtration rate (eGFR) was calculated
using the CKD-EPI cystatin C equation: eGFR = 133 ×
min(serum cystatin C/0.8, 1)-0.499 × max(serum cystatin
C/0.8, 1)-1.328 × 0.996age [×0.932 if female] [17].
Metabolomics measurements
A detailed description of all applied measurement tech-
niques is provided in the Supplemental information. The
following passage briefly summarizes the most important
steps.
Metabolomics measurements based on MS
Non-targeted metabolomics analysis for metabolic pro-
filing was conducted at the Genome Analysis Center,
Helmholtz Zentrum München, Germany. Briefly, two
separate LC-MS/MS analytical methods were used as
previously published [18] to obtain broad metabolite
spectra in plasma and urine samples in a non-targeted
manner. After pre-processing, 475 plasma and 558 urine
metabolites remained for the statistical analyses. Note
that 177 plasma metabolites and 302 urine metabolites
could not be unambiguously assigned to a chemical
identity and are referred to hereafter with the notation
“X” followed by a unique number.
Targeted metabolomics profiling of the plasma sam-
ples was performed using the AbsoluteIDQ p180 Kit
(BIOCRATES LifeSciences AG, Innsbruck, Austria, on-
line supplementary methods) and was conducted at the
Institute of Clinical Chemistry and Laboratory Medicine,
Universtiy Medicine Greifswald, Germany. This ap-
proach allows simultaneous absolute quantification of
188 metabolites using a combination of liquid chroma-
tography (Agilent 1260 Infinity Binary LC, Santa Clara,
United States) and mass spectrometry (AB SCIEX 5500
QTrap™ mass spectrometer; AB SCIEX, Darmstadt,
Germany). After normalization and pre-processing of
the data, 183 metabolites were available for subsequent
analysis.
Metabolomics measurements based on 1H-NMR
Urine samples were measured on a Bruker DRX-400
NMR Spectrometer (Bruker BioSpin GmbH, Rheinstetten,
Germany) operating at a 1H frequency of 400.13 MHz fol-
lowing a published workflow [19]. The Fourier-transformed
and baseline-corrected NMR spectra were manually an-
notated by spectral pattern matching using Chenomx
NMR Suite 6.1 (Chenomx Inc., Edmonton, Alberta,
Canada) to deduce absolute urinary concentrations of
51 metabolites.
Data integration
Most of the metabolites were unique to one of the ap-
plied techniques. However, 44 and 22 metabolites in
plasma and urine, respectively, were overlapping with at
least one other technique. With respect to plasma, fol-
lowing the grouping of metabolites in biochemical clas-
ses (i.e., lipids, amino acids and carbohydrates),
correlations of those metabolites measured on both plat-
forms were computed with all members of the same bio-
chemical class. Subsequently, the metabolite with the
higher median correlation across all class members was
kept for further analysis. Regarding the lower sensitivity
of NMR compared to MS, in cases of duplicated mea-
sures, those obtained on the MS were kept for further
analyses. In total, 613 plasma and 587 urine metabolites
were used in the subsequent statistical analyses.
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Statistical analysis
Continuous data are expressed as median (25th–75th
quartile) and nominal data are expressed as percentage.
For bivariate analyses, the Mann–Whitney U-test (con-
tinuous data) or χ2 test (nominal data) were used to
compare women and men. Linear regression models
were performed to assess the association between in-
flammatory markers, namely, hsCRP, WBC, and fibrino-
gen (independent), and plasma and urine metabolites
(dependent). Concentrations of all metabolites as well as
hsCRP levels were log-transformed to fulfil the require-
ments of linear regression. Models were adjusted for
age, sex, waist circumference, smoking behavior and
physical activity. To avoid spurious results in linear re-
gression analysis, univariate outliers for each metabolite
were excluded whenever concentrations exceeded more
than three standard deviations from the mean value.
Sensitivity analyses on the influence of latent diabetic
subjects (n = 29; meeting one of the following criteria:
(1) fasting glucose > 11.1 nmol/L, or (2) HbA1c > 6.5%,
or (3) intake of diabetic medication (ATC code A10))
was performed by exclusion of those subjects. To
account for multiple testing, we adjusted the P values
from regression analyses by controlling the false discov-
ery rate (FDR) at 5% using the Benjamini–Hochberg
procedure.
Classification analyses were performed to prove the
discriminative ability of the metabolome as well as to
highlight central metabolites. As no established cut-offs
for low-grade inflammation exist we defined an ad-
vanced inflammatory state using the population distribu-
tions of the inflammatory markers, i.e., participants with
hsCRP, WBC, and fibrinogen levels, by denoting all of
those in the upper quartile as having an advanced in-
flammatory state. In contrast, a healthy state was defined
as being consistently in the lower quartile of inflamma-
tory markers. As a result, 42 and 54 subjects presented
with low or high inflammatory conditions, respectively.
For classification purposes, a random forest was applied
embedded in a two-stage cross-validation procedure
(Additional file 1: Figure S2). The random forest was imple-
mented in R via the randomForest package (v 4.6-10) [20].
This combination allowed for variable selection and valid-
ation of a defined subset (limited to 10 metabolites), even
in the absence of an independent test set. Further, evalu-
ation of multiple permutations among training, testing, and
validation sets allowed us (1) to achieve a reliable estimate
of the discriminative performance of the metabolome and
(2) to judge the consistency of the named markers to dis-
criminate an inflammatory state. For this purpose, 872 me-
tabolites with less than 20% missing values were chosen
along with participant age, sex, waist circumference, and
eGFR as additional variables. Missing values were imputed
using the k-nearest neighbor technique as implemented in
the R package impute, setting k to 10.
Statistical analyses were performed using SAS version
9.4 (SAS statistical software, version 9.4, SAS Institute,
Inc., NC, USA) and R 3.1.1 (R Foundation for statistical
computing, version 3.1.1, Vienna, Austria).
Results
The general characteristics of the study population are
provided in Table 1. Men and women were 50 years old
on average. Men were less often never smokers, had a
Table 1 General characteristics of the study population
Men (n = 415) Women (n = 510) P
Age, years 50 (40–61) 51 (41–60) 0.86
Smoking, % <0.01
Never smoker 30.8 50.6
Ex-smoker 46.0 29.2
Current smoker 23.1 20.2
Physical activity (≥1 h per week), % 72.8 73.5 0.82
Waist circumference, cm 94 (87–102) 81 (74–90) <0.01
Glucose, mmol/L 5.4 (5.1–5.8) 5.2 (4.9–5.6) <0.01
Triglycerides, mmol/L 1.32 (0.93–1.93) 1.16 (0.85–1.61) <0.01
Cholesterol, mmol/L 5.4 (4.6–6.1) 5.5 (4.9–6.3) <0.01
eGFR, mL/min/1.72 m2 117 (108–125) 112 (103–121) <0.01
WBC, Gpt/L 5.34 (4.64–6.35) 5.50 (4.78–6.47) 0.18
Fibrinogen, g/L 2.80 (2.30–3.30) 3.10 (2.60–3.50) <0.01
hsCRP, mg/L 1.00 (0.55–1.83) 1.26 (0.67–2.83) <0.01
Continuous data are expressed as median (25th percentile–75th percentile); nominal data are given as percentages
*χ2 (nominal data) or Mann–Whitney (interval data) tests were performed
eGFR estimated glomerular filtration rate, WBC white blood cell count, hsCRP high-sensitive C-reactive protein
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higher waist circumference, and exhibited higher levels
of glucose, triglycerides, and eGFR, whereas cholesterol
levels were slightly lower compared to those of women.
With respect to inflammatory markers, no differences
were detected for WBC, whereas fibrinogen and hsCRP
were lower in men than in women.
Associations with inflammatory markers in the plasma
metabolome
HsCRP, WBC, and fibrinogen showed significant associ-
ations with 71, 20, and 19 out of 613 plasma metabolites,
respectively; none was common to all traits (Fig. 1,
Additional file 2: Table S1). Bradykinin metabolites,
biliverdin, gamma-glutamylmethionine, the sphingo-
myelin C24:1, the amino acids glutamine, glycine and
serine, and some compounds with unknown chemical
identity were shared by at least two of the assessed
traits. A wealth of unique associations with hsCRP be-
came apparent, including positive associations with in-
termediates of branched-chain amino acid and lysine
degradation (e.g., valine or pipecolate (Figs. 1 and 2)),
acylcarnitines, long-chain fatty acids, further sphingo-
myelins, and diacylphosphatidylcholines, as well as cor-
tisol levels (Fig. 2). Significant inverse associations with
hsCRP became apparent with respect to members of
the urea cycle and several lysophosphatidylcholines
(lysoPC) containing (poly)unsaturated fatty acids (e.g.,
lysoPC 18:1 and 18:2; Fig. 2). The most prominent find-
ings unique to WBC were the positive associations with
lactate, pyruvate, sphingosine, and hexadecanedioate.
Unique associations with fibrinogen were observed for
plasma levels of pregnanediol-3-glucuronide (positively)
and phosphatidylcholines with fatty acid residues bound
to one acyl and one alkyl group (inversely).
Fig. 1 Color coded corrected P values (controlling the false discovery rate (FDR) at 0.05) from linear regression analyses for the association of
high-sensitivity C-reactive protein (hsCRP), white blood cell count (WBC), or fibrinogen with plasma (upper panel) or urine metabolites (lower left
panel). Significant associations (FDR < 0.05) are marked with a dot. All analyses were adjusted for age, sex, waist circumference, smoking behavior,
and physical activity. Orange and blue shading indicate positive and negative associations, respectively. Corresponding beta estimates and FDR
values are given in Additional file 2: Tables S1 and S2. Lower right panel: Venn diagrams depict the overlap in significantly associated metabolites
to each trait in plasma and urine
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Associations with inflammatory markers in the urine
metabolome
In general, associations with urinary metabolites were
less frequent compared with plasma metabolites (Fig. 1
and Additional file 2: Table S2); HsCRP, WBC, and
fibrinogen showed significant associations with 22, 3,
and 16 out of 587 urine metabolites, respectively (Fig. 1).
A positive association with the disaccharide 3’-sialyllac-
tose was common to all investigated traits; further, it
was the strongest association within the present study
(Fig. 1 and Additional file 2: Table S2). The related
metabolite N-acetylneuraminate (sialic acid) was posi-
tively associated with hsCRP and fibrinogen similarly to
C-mannosyltryptophan (Fig. 2) and the unknown X-
14302. Similar to plasma, hsCRP comprised most of the
unique associations (Fig. 1), including homocitrulline,
taurocholate sulfate and several unknown compounds
(positively) as well as glycine, 2-aminooctanoate, glycyl-
proline, and 7-methylguanine (inversely). Unique associ-
ations with fibrinogen consisted of 3-ureidopropionate,
hexanoylglycine, 5-alpha-pregnan-3-beta,20-alpha-diol
disulfate, o-cresol sulfate, and the xenobiotics 3-
ethylphenylsulfate and cotinine N-oxide.
The vast majority of the presented results remained
stable after exclusion of 29 latent diabetic subjects
(Additional file 1: Figure S3). Single departures might be
most likely due to random variation as comparison be-
tween the false discovery rate values of the whole and the
subpopulation revealed no gross effects (Additional file 1:
Figure S3).
Predicting an advanced inflammatory state
In addition to association testing, we searched for a dis-
criminative signature between healthy participants (only
low inflammatory markers) and an advanced inflammatory
state, defined as the consistent presence of inflammatory
markers in the highest quartile among the present cohort
(n = 54). To this end, we applied a random forest analysis
embedded in a two-stage cross-validation procedure com-
bining variable selection with model evaluation. We
achieved moderately robust classification as shown by a
median area under the receiver operating characteristic
curve of 0.83 across 20 validation runs using a subset of 10
metabolites (Fig. 3). The approach clearly highlights the
importance of five metabolites, consisting of three
plasma metabolites, lysoPC 18:2, adenosine 5’-phos-
phate, and glutamate, as well as two urine metabolites,
C-mannosyltryptophan and 3’-sialyllactose.
Discussion
Chronic low-grade inflammation as reflected by elevations
in blood parameters, such as hsCRP, WBC, or fibrinogen,
is accompanied by a multitude of metabolic changes. In
an attempt to comprehensively characterize such changes,
the present study used a state-of-the-art metabolomics ap-
proach comprising non-targeted and targeted techniques
in an apparently healthy sample of the general population.
The absence of acute inflammatory processes as well as
diabetic cases allowed the profiling of subclinical molecu-
lar patterns. This profiling provided novel insights in al-
tered pathways possibly contributing to the adverse effect
of inflammatory processes on metabolic and cardiovascu-
lar diseases. Urinary metabolites in particular might be
promising biomarkers to ease the diagnosis and monitor-
ing of inflammation-associated diseases.
The bradykinin systems as proof of principle
One common feature of hsCRP and fibrinogen indicating
low-grade inflammation was the increased appearance of
bradykinin metabolites in plasma. Bradykinin, as part of the
kinin-kallikrein system, is released from high-molecular-
weight kininogen upon interaction with kallikrein, which in
Fig. 2 Predicted least square means with 95% confidence intervals from linear regression analyses using quartiles of high-sensitivity C-reactive protein
(hsCRP) as exposure controlling for age, sex, waist circumference, physical activity and smoking
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turn is activated by factor XIIa in the course of activated
coagulation [21]. Once released, bradykinin acts as a vaso-
active peptide hormone via binding to bradykinin receptors,
B1 and B2, in the vascular endothelium and induces the
classical symptoms of inflammation, i.e., swelling and red-
ness [21]. However, increasing vascular permeability and
enhancement of smooth muscle tone are only two of sev-
eral mechanisms of bradykinin action [22]. Bradykinin plays
a particularly important role in various classifications of an-
gioedema, but also in other inflammatory processes such as
allergic rhinitis [21]. Conflicting reports exist about its rela-
tion with the cardiovascular system. Moreover, bradykinin
production leads to the release of various cytokines [23],
e.g., IL-6, which further activates the innate immune system
and, thereby, CRP release from the liver. In this respect,
our findings mirror previously described biological path-
ways emphasizing the validity of the presented approach.
Metabolites linked to an oxidative stress signature
The strongest associations with respect to amino acids
were demonstrated for plasma levels of glutamine (nega-
tively) and pipecolate (positively) (Fig. 2). Pipecolate, a
metabolite in the degradation of the essential amino acid
lysine, has shown antioxidative properties in a number
of cell and animal models [24]. A possible explanation
for its association with hsCRP might be an increased
demand of antioxidant agents during inflammation in
tissues highly active in respiration. One opportunity to
compensate the increased energy demand accompanied
by inflammatory processes would be an increased
utilization of fat from deposits, such as white adipose
tissue. Indeed, within the present study, an increase in
hsCRP was associated with increased plasma levels of
free fatty acids. After uptake in respiratory active tissues,
free fatty acids are subjected to oxidation within the
mitochondria. To pass the outer mitochondrial mem-
brane, the fatty acids have to be conjugated with carni-
tine, yielding acylcarnitines. In situations of pronounced
lipolysis and respiration, these intermediates are likely to
be spilled into the circulation, which is further supported
by our observations. A possible mediator in this context
might be the elevated cortisol concentrations observed
in the present study. Cortisol is well-known to counter-
act a prolonged inflammatory milieu by diminishing the
production of pro-inflammatory mediators, including IL-
12, IFN-γ, or TNF-α, at the transcriptional level. Import-
antly, the interrelation between cortisol and cytokines is
mutual. An acute injection of cytokines led to a rise in
cortisol levels, seen as an adaptive response to fulfil the
increased energy demand of inflamed tissues [25]. Con-
sistently, an experimental study in healthy volunteers
[26] showed a cortisol-dependent induction of lipolysis
from femoral and abdominal adipose tissue.
It should be noted that even microbiota are able to pro-
duce pipecolate [27] when given lysine as a substrate, and
host dysbiosis is a hallmark of many inflammatory
diseases [28, 29]. As a direct link between plasma pipeco-
late levels and composition of the gut microbiota has not
Fig. 3 Final results from classification analyses using random forests in a two-stage cross-validation scheme with 20 inner and 20 outer loops
(Additional file 1: Figure S1). Left panel: Ten most important metabolites ranked by a weighted (area under the curve) mean Gini index (orange
triangle). Boxplots indicate distribution across 20 outer runs. Right panel: Receiver operating characteristic (ROC) curve and boxplot of the area
under the curve from 20 outer loops. Overlapping ROCs are displayed by darker shades
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been available up to now, further studies are needed to
investigate this possible line of explanation in more detail.
In contrast to the positive association with pipecolate,
we observed a significant inverse association of hsCRP
with glutamine and to a lesser extent with WBC. The
non-essential amino acid glutamine attenuated inflam-
matory signs when given as a supplement in clinical
applications for patient recovery after abdominal surgery
[30] and in the perioperative period [31, 32], as well as
in patients who needed intensive care. In addition to the
lowering of inflammatory markers, e.g., hsCRP, TNF-α,
or IL-6, even surrogates of intestinal permeability were
reduced [30]. The authors concluded that glutamine is
able to effectively reduce inflammation. This finding is
in concordance with the inverse association between
hsCRP and glutamine in the present study. It is known
that glutamine, as a precursor of glutathione, plays a
crucial role in the prevention of oxidative damage in the
human body [33] and thus also has a positive influence
on the maintenance of the gastrointestinal barrier [30]
and the endothelial function of the blood vessels [34].
An intervention study among women of advanced age
showed that a 6-month administration of amino acids,
including glutamine, significantly reduced hsCRP and
thus has potential beneficial effects [34].
Inverse association between inflammation and members
of the urea cycle
In addition to its role as precursor of glutathione, glutam-
ine is implicated in arginine metabolism. Arginine is an
amino acid of the urea cycle [35] and was inversely associ-
ated with hsCRP in the present study. Previous investiga-
tions have suggested an immune-modulating effect [36]
and anti-inflammatory properties [37] of arginine. Alter-
ations in the urea cycle with respect to hsCRP were fur-
ther highlighted by inverse associations with the plasma
metabolites ornithine and citrulline as well as a strong
association with urinary homocitrulline. The latter is
detected in large quantities in urine in cases of urea cycle
disorders [38]. These findings might be a general feature
of (severe) inflammatory conditions, as a previous study
observed decreased levels of urea cycle intermediates in
subjects with sepsis and trauma [39]. Interestingly, during
the recovery phase and in the reduction of inflammation,
a rise in arginine and citrulline levels were observed.
Furthermore, among critically ill patients, low plasma
citrulline levels were related to low levels of arginine and
glutamine as well as elevated hsCRP levels [40]. Even if
the underlying mechanisms are not yet understood in
detail, it can be assumed that glutamine, with its central
position in metabolism, plays a crucial role in inflamma-
tion. However, longitudinal studies are needed to assess
the possible anti-inflammatory effect of high baseline
glutamine concentrations.
Phospholipids as potential inflammatory mediators
A very prominent molecular signature associated with
hsCRP consisted of lysoglycerophospholipds with cho-
line (lysoPC), inositol, or ethanolamine as the head-
group and unsaturated fatty acids as residues merely in
an inverse manner. Lysoglycerophospholipds are derived
from hydrolysis of phospholipids and this might point
towards diminished phospholipase A1 or A2 activity. In
contrast to our findings, several lines of evidence suggest
increased phospholipase activity under inflammatory
conditions [41–43]. A diminished production could
therefore be reasonable, as one of the primary precur-
sors of lysoPC, glycerophosphorylcholine, also decreased
with increasing hsCRP levels. LysoPCs have often been
discussed as pro-inflammatory molecules with regard to
acute and chronic inflammation and atherosclerosis [44]
and are strongly suspected to be associated with inflam-
matory diseases, e.g., rheumatoid arthritis [45]. LysoPCs
transport fatty acids, phosphatidylglycerol, and cholines
between different tissues, but also activate signaling
pathways leading to the release of second messengers
[44] as ligands for G protein-coupled receptors [44].
Thus, they are able to promote the release of pro-
inflammatory factors in endothelial cells – an important
mechanism in the development of arteriosclerosis [46].
Interestingly, population-based studies revealed inverse
associations between lysoPC 18:1 and 18:2 with the risk
of developing T2DM [47] or the onset of coronary heart
disease [48]. Given that a chronic inflammatory environ-
ment is a hallmark of such diseases, our observation of
an inverse association with hsCRP potentially further
argues for a functional implication of lysoPCs in the
mediation between inflammation and associated dis-
eases. The latter might be further supported by the miss-
ing effect of the exclusion of latent diabetic subjects on
the observed associations between lysoPC 18:1 and 18:2
and hsCRP levels.
3’-sialyllactose as a novel link to inflammation
The urinary metabolite 3’-sialyllactose showed the stron-
gest association and was positively related to all investi-
gated traits. 3'-sialyllactose belongs to the group of
oligosaccharides, which are generally components of
milk and have a protective, immune-modulating influ-
ence on the development of neonates [49, 50]; 3'-sialyl-
lactose is composed of sialic acid (N-acetylneuraminic
acid) and lactose [51]. Interestingly, even urinary sialic
acid levels rose under inflammatory conditions, particu-
larly in respect to fibrinogen levels but also to hsCRP
within the present study. Sialic acid forms the outer end
of the sugar branches representing the glycocalyx [52, 53]
and exerts influence on immune reactions in different
ways [53]. Briefly, sialic acid takes part in the development
of B and T cells [54, 55] and plays a role in the interaction
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of immune cells with other cells [56]. The diapedesis of
leucocytes [57] is mediated by cellular adhesion molecules
with selectins and sialic acid representing important com-
ponents of ligands, which can bind to the selectin family
of the cell adhesion molecules. A positive relation between
sialic acid and hsCRP was reported among 48 patients
with chronic cardiac insufficiency, and the authors postu-
lated both as reliable markers of systemic inflammation in
chronic heart failure patients [58]. Moreover, sialic acid
appears to be a pro-inflammatory marker not only in the
case of chronic cardiac insufficiency, but also in other car-
diovascular diseases such as deep venous thrombosis [59],
T2DM [60], and the T2DM-associated sequelae diabetic
nephropathy [61]. These findings are in good agreement
with the positive association of sialic acid or 3'-sialyllac-
tose and hsCRP in our study. As already mentioned with
respect to the lysoPCs, even the association with 3-
siallylactose was not affected by the exclusion of latent
diabetic subjects and thus might point towards elevated 3-
siallylactose levels as a preceding event. More astonishing
is the discrepancy with the above-mentioned protective,
immune-modulating effects of 3'-sialyllactose in neonates
[49, 50]. It would be conceivable that the immune-
promoting, anti-inflammatory effects of 3'-sialyllactose are
only effective in newborns whose immune systems are still
developing, whereas in adults, apparently the exact oppos-
ite effect is achieved. This situation should be further
investigated through intervention studies.
Similarities and difference between inflammatory
surrogates
The strong differences observed in the metabolic signa-
tures for each of the inflammatory traits must be dis-
cussed. All markers were of different specificity for the
inflammatory process and, from a statistical point of
view, were only moderately intercorrelated (Additional
file 1: Figure S3). With respect to an acute inflammatory
response, CRP, fibrinogen, and WBC belong to different
stages of the acute phase response with different
temporal patters of accumulation [62, 63]. However, the
present study focused on a low-grade inflammatory state
characterized by mildly elevated hsCRP, WBC, or
fibrinogen levels. The difference between hsCRP and
WBC may be due to their different origins and roles
during a chronic inflammatory response. CRP (and
fibrinogen) are produced and secreted by the liver upon
IL-6 stimulation and subsequently reach the site of
inflammation through circulation. Even leucocytes reach
the inflammatory site through circulation following
release from the bone marrow. However, the inflamma-
tory state of, for example, adipose tissue, in the course
of low-grade inflammation is not primarily due to newly
arriving immune cells but rather due to the polarization
of resistant macrophages secreting cytokines, such as IL-
6, which in turn stimulate the liver to secrete, among
others, CRP. In conclusion, the differing metabolic pro-
files observed reflect the distinct physiological roles of
the parameters. Even though the latter might be obvious,
our results further argue for a distinct discussion of a
low-grade inflammatory state dependent on the markers
used to define it. The prominent role of CRP might
thereby most likely be due to its long half-life, the highly
sensitive assay applied, and its non-specific nature
reflecting multiple distinct processes.
With respect to the different association profiles of all
considered markers the unique positive relation between
WBC and the carbohydrates lactate and pyruvate might
be of particular interest. Lactate is known to accumulate
at sites of inflammation [2], not only due to hypoxic
conditions forcing the switch to aerobic glycolysis, but
also to meet the general demands of the highly prolifera-
tive immune cells. Moreover, lactate itself was recently
shown to modulate the pro-inflammatory response of T
cells [64]. Importantly, lactate induced the trapping of T
cells at the site of inflammation and thus the persistence
of pro-inflammatory signaling.
A predictive metabolic signature
Random forest analyses revealed a good capacity of the
metabolome to predict an advanced inflammatory state.
Within this signature, four metabolites were clearly dis-
tinguished as they were robustly included in the final
classifier independently of the subpopulation used. The
possible relation between lysoPC 18:1 and urinary 3’-sia-
lylactose has already been discussed in the previous sec-
tions. C-mannosyltryptophan is a product derived from
the C-glycosylation of the aromatic amino acid trypto-
phan and mannose. Previous studies noted a strong age-
dependency of plasma C-mannosyltryptophan [65, 66],
likely due to its strong dependency on renal filtration
[67, 68]. However, neither age nor eGFR emerged as
comparable predictive variables in the classification pro-
cedure. In the context of inflammation, it might be of
interest that C-glycosylated tryptophan can also be
found in IL-12 and components of the complement
system [69]. However, all of these studies refer to plasma
levels of C-mannosyltrytophan and, even if these were
also associated with hsCRP within the present study, the
possible interplay of kidney function and inflammation
warrants further investigation given the pronounced
association observed in urine.
A note on the applicability of our findings
The comprehensive metabolic picture of low-grade
inflammation drawn in the present study is useful for
different kinds of research. Our results add a subclinical
inflammatory state as an important determinant of the
metabolome, which has to be considered in future
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metabolomics studies not only to avoid artificial findings
but also to interpret metabolic patterns observed. The
latter is of particular interest as metabolomics is a rather
young scientific branch and the knowledge about its
modulators is still incomplete. Further, key metabolites
discussed and presented here are valuable targets for
future studies to improve the diagnosis and treatment of
inflammatory-associated diseases. Moreover, those me-
tabolites might further provide molecular links between
a low-grade inflammatory state and metabolic disease as
small molecules are increasingly recognized as mediators
in disease progression [70].
Strengths and limitations
An undeniable strength of our study is the combination
of a large sample size, the comprehensive profiling of
the metabolome, and the measurement of three clinically
important inflammatory parameters. All participants
were apparently healthy with respect to acute inflamma-
tion. Thus, we were able to (1) confirm previous findings
concerning known associations, (2) gain deeper insights
in the broad field of metabolomics, and (3) give recom-
mendations for new possible markers indicating low-
grade inflammation. However, it must be mentioned
that, due to the cross-sectional design of our investiga-
tion, no conclusions can be drawn about the causalities
of the found associations. Intervention studies are neces-
sary to investigate the metabolic fingerprint of inflam-
mation causally. Additional studies should be performed
profiling the metabolic signatures of other established
inflammatory markers, such as IL-6 or TNF-α, in order
to augment the acquired findings, in particular with
respect to the remission of inflammation. As our study
addressed a low-grade inflammatory state in particular,
further studies in cohorts of patients suffering from in-
flammatory disease, e.g., arthritis or chronic pancreatitis,
are required to judge the clinical usefulness of the pre-
sented metabolic markers of inflammation. With respect
to possible bystander effects, we could not rule out
hidden mediation not captured by the data obtained for
the study population.
Conclusions
We were the first to investigate the metabolic profile of
an apparently healthy sample of the general population
regarding its association with three clinically important
representatives of inflammatory parameters. We ob-
served an extensive picture of various associated plasma
and urine metabolites, among them classical representa-
tives of inflammation, e.g., the bradykinin system. Im-
portantly, we were able to describe novel metabolites
that were not yet investigated with regards to their con-
nection with inflammation such as 3’-sialyllactose; these
may prove potential, novel non-invasive biomarkers for
low-grade inflammatory processes. As the link between
metabolism and inflammation is an understudied
phenomenon [11], our study suggests promising bio-
markers for the actions of hsCRP, WBC, and fibrinogen
on metabolism, which promise potential support in diag-
nosis and prognosis. Further, a preventive aspect might
be of interest, for example, as shown for the inverse rela-
tion between glutamine and hsCRP, which was attenu-
ated by glutamine supplementation. Similar strategies
may be possible for other central metabolites named in
the present study.
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